Lexeo Therapeutics, Inc.
LXEO
$5.13
$0.42198.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -82.73% | -46.65% | -58.00% | -16.21% | 2.68% |
| Total Depreciation and Amortization | 6.33% | 10.65% | 11.21% | 6.49% | 10.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 228.06% | 231.00% | 193.70% | 487.15% | 103.84% |
| Change in Net Operating Assets | -376.00% | 62.14% | -93.65% | 814.44% | 55.36% |
| Cash from Operations | -102.60% | -27.65% | -52.76% | 19.09% | 15.91% |
| Capital Expenditure | 100.00% | -2,666.67% | -446.15% | -- | -192.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | 100.00% |
| Cash from Investing | -128,095.89% | -56.60% | -458.97% | -- | 31.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -10.48% | -3.74% | 28.16% | 0.91% | 2.78% |
| Issuance of Common Stock | -93.70% | 30.00% | 4,100.00% | 739,591.67% | 357,939.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8,284.00% | -- | -- | -- | -- |
| Cash from Financing | -100.10% | -101.84% | 409.57% | 90,563.27% | 123,644.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -241.84% | -78.01% | -50.69% | 498.41% | 611.58% |